Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both

It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therap...